Invention Grant
- Patent Title: BTLA fusion protein agonists and uses thereof
-
Application No.: US17188912Application Date: 2021-03-01
-
Publication No.: US11939367B2Publication Date: 2024-03-26
- Inventor: Carl F. Ware , John Sedy , Tigran Aivazian , Brian Miller , Natasha K. Crellin
- Applicant: Sanford Burnham Prebys Medical Discovery Institute , PFIZER INC.
- Applicant Address: US CA La Jolla
- Assignee: Sanford Burnham Prebys Medical Discovery Institute,Pfizer Inc.
- Current Assignee: Sanford Burnham Prebys Medical Discovery Institute,Pfizer Inc.
- Current Assignee Address: US CA La Jolla; US NY New York
- Agency: McNeill Baur PLLC
- The original application number of the division: US15737259
- Main IPC: C07K14/705
- IPC: C07K14/705 ; A61K38/17 ; A61K45/06 ; A61K47/68 ; C07K14/71 ; C07K14/715 ; C07K19/00 ; A61K38/00
Abstract:
The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
Public/Granted literature
- US20220025017A1 BTLA FUSION PROTEIN AGONISTS AND USES THEREOF Public/Granted day:2022-01-27
Information query
